Eric Joseph
Stock Analyst at JP Morgan
(1.37)
# 3,547
Out of 4,987 analysts
126
Total ratings
38.37%
Success rate
-10.38%
Average return
Main Sectors:
Stocks Rated by Eric Joseph
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Overweight | $57 → $64 | $51.16 | +25.10% | 4 | Jun 3, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $5.12 | - | 5 | May 20, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $45 → $44 | $3.17 | +1,288.01% | 3 | May 9, 2025 | |
| NVAX Novavax | Maintains: Underweight | $9 → $7 | $8.53 | -17.94% | 8 | May 9, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $75 → $67 | $62.88 | +6.55% | 10 | May 7, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.51 | - | 4 | Apr 25, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Neutral | n/a | $1.49 | - | 4 | Feb 10, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $31 → $30 | $8.97 | +234.45% | 7 | Jan 29, 2025 | |
| VIR Vir Biotechnology | Maintains: Neutral | $10 → $14 | $5.18 | +170.27% | 5 | Jan 9, 2025 | |
| RVMD Revolution Medicines | Maintains: Overweight | $63 → $71 | $45.22 | +57.01% | 6 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $43 | $32.61 | +31.86% | 4 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $15.94 | +138.39% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $2.50 | +820.00% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $6.96 | +144.25% | 2 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $4.55 | +361.54% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $48 | $25.10 | +91.24% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $7.83 | +27.71% | 4 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.09 | - | 4 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $15 | $2.08 | +621.15% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6 | $3.32 | +80.72% | 4 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $11 → $10 | $4.93 | +102.84% | 2 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $11 | $6.93 | +58.73% | 2 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $41 | $46.20 | -11.26% | 2 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $300 → $100 | $12.68 | +688.64% | 1 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 → $5 | $0.51 | +886.19% | 2 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.99 | - | 6 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $11 | $8.18 | +34.47% | 6 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $11.81 | - | 2 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 | $5.73 | +1,994.24% | 2 | Feb 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $750 → $300 | $9.99 | +2,903.00% | 2 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $4.26 | - | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $24 → $9 | $1.36 | +561.76% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.96 | - | 4 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $3.35 | +1,153.73% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 → $13 | $1.46 | +790.41% | 2 | Jan 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $11 | $0.55 | +1,900.00% | 3 | Nov 14, 2018 |
Kymera Therapeutics
Jun 3, 2025
Maintains: Overweight
Price Target: $57 → $64
Current: $51.16
Upside: +25.10%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $5.12
Upside: -
Rocket Pharmaceuticals
May 9, 2025
Maintains: Overweight
Price Target: $45 → $44
Current: $3.17
Upside: +1,288.01%
Novavax
May 9, 2025
Maintains: Underweight
Price Target: $9 → $7
Current: $8.53
Upside: -17.94%
PTC Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $75 → $67
Current: $62.88
Upside: +6.55%
OPKO Health
Apr 25, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.51
Upside: -
Pliant Therapeutics
Feb 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.49
Upside: -
Nurix Therapeutics
Jan 29, 2025
Maintains: Overweight
Price Target: $31 → $30
Current: $8.97
Upside: +234.45%
Vir Biotechnology
Jan 9, 2025
Maintains: Neutral
Price Target: $10 → $14
Current: $5.18
Upside: +170.27%
Revolution Medicines
Dec 3, 2024
Maintains: Overweight
Price Target: $63 → $71
Current: $45.22
Upside: +57.01%
Nov 25, 2024
Maintains: Overweight
Price Target: $30 → $43
Current: $32.61
Upside: +31.86%
Nov 19, 2024
Initiates: Overweight
Price Target: $38
Current: $15.94
Upside: +138.39%
Nov 5, 2024
Initiates: Overweight
Price Target: $23
Current: $2.50
Upside: +820.00%
Oct 17, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $6.96
Upside: +144.25%
Sep 10, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $4.55
Upside: +361.54%
Aug 7, 2024
Maintains: Overweight
Price Target: $45 → $48
Current: $25.10
Upside: +91.24%
Aug 6, 2024
Maintains: Underweight
Price Target: $11 → $10
Current: $7.83
Upside: +27.71%
Jul 8, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.09
Upside: -
May 3, 2024
Maintains: Neutral
Price Target: $14 → $15
Current: $2.08
Upside: +621.15%
Jan 29, 2024
Upgrades: Neutral
Price Target: $6
Current: $3.32
Upside: +80.72%
Nov 13, 2023
Maintains: Neutral
Price Target: $11 → $10
Current: $4.93
Upside: +102.84%
Oct 19, 2023
Maintains: Overweight
Price Target: $31 → $11
Current: $6.93
Upside: +58.73%
Oct 11, 2023
Maintains: Overweight
Price Target: $62 → $41
Current: $46.20
Upside: -11.26%
Aug 28, 2023
Downgrades: Neutral
Price Target: $300 → $100
Current: $12.68
Upside: +688.64%
Aug 28, 2023
Downgrades: Neutral
Price Target: $28 → $5
Current: $0.51
Upside: +886.19%
Aug 10, 2023
Downgrades: Underweight
Price Target: n/a
Current: $2.99
Upside: -
Aug 9, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $8.18
Upside: +34.47%
Nov 29, 2022
Downgrades: Underweight
Price Target: n/a
Current: $11.81
Upside: -
Feb 9, 2022
Upgrades: Neutral
Price Target: $120
Current: $5.73
Upside: +1,994.24%
Jan 7, 2022
Downgrades: Neutral
Price Target: $750 → $300
Current: $9.99
Upside: +2,903.00%
Oct 8, 2021
Downgrades: Underweight
Price Target: n/a
Current: $4.26
Upside: -
Jan 29, 2021
Downgrades: Neutral
Price Target: $24 → $9
Current: $1.36
Upside: +561.76%
Jan 29, 2021
Downgrades: Underweight
Price Target: n/a
Current: $2.96
Upside: -
Feb 24, 2020
Initiates: Overweight
Price Target: $42
Current: $3.35
Upside: +1,153.73%
Jan 24, 2019
Upgrades: Neutral
Price Target: $11 → $13
Current: $1.46
Upside: +790.41%
Nov 14, 2018
Maintains: Neutral
Price Target: $35 → $11
Current: $0.55
Upside: +1,900.00%